CA2964948A1 - Altering gene expression in modified t cells and uses thereof - Google Patents

Altering gene expression in modified t cells and uses thereof Download PDF

Info

Publication number
CA2964948A1
CA2964948A1 CA2964948A CA2964948A CA2964948A1 CA 2964948 A1 CA2964948 A1 CA 2964948A1 CA 2964948 A CA2964948 A CA 2964948A CA 2964948 A CA2964948 A CA 2964948A CA 2964948 A1 CA2964948 A1 CA 2964948A1
Authority
CA
Canada
Prior art keywords
cells
cell
tcr
modified
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2964948A
Other languages
English (en)
French (fr)
Inventor
Yangbing Zhao
Jiangtao REN
Xiaojun Liu
Carl H. June
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2964948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2964948A1 publication Critical patent/CA2964948A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2964948A 2014-10-31 2015-10-15 Altering gene expression in modified t cells and uses thereof Pending CA2964948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073651P 2014-10-31 2014-10-31
US62/073,651 2014-10-31
PCT/US2015/055780 WO2016069282A1 (en) 2014-10-31 2015-10-15 Altering gene expression in modified t cells and uses thereof

Publications (1)

Publication Number Publication Date
CA2964948A1 true CA2964948A1 (en) 2016-05-06

Family

ID=55858177

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2964948A Pending CA2964948A1 (en) 2014-10-31 2015-10-15 Altering gene expression in modified t cells and uses thereof
CA2964953A Pending CA2964953A1 (en) 2014-10-31 2015-10-15 Altering gene expression in cart cells and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2964953A Pending CA2964953A1 (en) 2014-10-31 2015-10-15 Altering gene expression in cart cells and uses thereof

Country Status (13)

Country Link
US (8) US20170335331A1 (https=)
EP (4) EP4219725A3 (https=)
JP (5) JP6879910B2 (https=)
KR (5) KR102546296B1 (https=)
CN (3) CN107249606A (https=)
AU (4) AU2015339743C1 (https=)
BR (1) BR112017008693A2 (https=)
CA (2) CA2964948A1 (https=)
EA (1) EA201790953A1 (https=)
ES (1) ES2983094T3 (https=)
MX (2) MX2017005698A (https=)
PL (1) PL3215166T3 (https=)
WO (2) WO2016069282A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865582A4 (en) * 2018-09-30 2022-07-13 Beijing DCTY Biotech Co., Ltd. HAFFT1 CELL

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3115457B1 (en) 2014-03-05 2019-10-02 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
EP3322424B1 (en) 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
JP6816133B2 (ja) 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
EP3359660B1 (en) 2015-10-05 2019-12-04 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
JP6923205B2 (ja) 2015-11-27 2021-08-18 国立大学法人神戸大学 標的化したｄｎａ配列の核酸塩基を特異的に変換する、単子葉植物のゲノム配列の変換方法、及びそれに用いる分子複合体
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
KR20190039115A (ko) * 2016-07-05 2019-04-10 더 존스 홉킨스 유니버시티 암을 치료하기 위한 crispr/cas9-기반 조성물 및 방법
CA3029860A1 (en) * 2016-07-05 2018-01-11 The Johns Hopkins University Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
CN106191062B (zh) * 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 一种tcr-/pd-1-双阴性t细胞及其构建方法
KR102546839B1 (ko) 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
BR112019002779A2 (pt) 2016-08-12 2019-05-14 Toolgen Incorporated elemento imunorregulador manipulado e imunidade alterada por este
IL308824A (en) * 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106399375A (zh) * 2016-08-31 2017-02-15 南京凯地生物科技有限公司 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
CN106480097A (zh) * 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
MX2019003768A (es) * 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
NZ753794A (en) * 2016-11-07 2023-05-26 Genovie Ab An engineered multi-component system for identification and characterisation of t-cell receptors, t-cell antigens and their functional interaction
DK4039800T5 (da) 2016-11-07 2024-07-29 Genovie Ab Konstrueret flerkomponentsystem til identifikation og karakterisering af t-cellreceptorer og t-cellantigener
JP6803480B2 (ja) 2016-11-07 2020-12-23 ジェノヴィー エービーＧｅｎｏｖｉｅ Ａｂ Ｔ細胞受容体の合成及びｔｃｒ提示細胞への安定なゲノム組込みのための二部分装置
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018132508A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Methods and compositions relating to ex vivo culture and modulation of t cells
WO2018132479A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
ES3064681T3 (en) * 2017-01-18 2026-04-28 Yeda Res And Development Co Ltd Genetically modified veto cells and use of same in immunotherapy
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
MX2019010906A (es) * 2017-03-14 2020-02-12 Juno Therapeutics Inc Metodos para almacenamiento criogenico.
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
CN110785489A (zh) * 2017-05-04 2020-02-11 宾夕法尼亚大学董事会 使用CRISPR/Cpf1在T细胞中进行基因编辑的组合物和方法
EP4029943A1 (en) * 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
JP7235391B2 (ja) 2017-05-08 2023-03-08 ツールゲン インコーポレイテッド 人工的に操作された免疫細胞
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MX2019013514A (es) 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
CN110944652A (zh) * 2017-06-12 2020-03-31 爱莫里大学 T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
CN109963944A (zh) * 2017-06-20 2019-07-02 江苏恒瑞医药股份有限公司 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA
WO2018236909A1 (en) * 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP3645038B1 (en) 2017-06-30 2026-02-18 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
US20200261502A1 (en) * 2017-09-08 2020-08-20 Carsgen Therapeutics Co., Ltd. Genetically engineered t cell and application thereof
EP3686275A4 (en) * 2017-09-18 2021-09-29 Edigene Inc. GENE EDITING LYMPHOCYTE T AND RELATED USE
KR20260026092A (ko) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
CN107630006B (zh) * 2017-09-30 2020-09-11 山东兴瑞生物科技有限公司 一种制备tcr与hla双基因敲除的t细胞的方法
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3702454A4 (en) 2017-10-10 2021-08-04 Hiroshima University METHOD FOR GENERATING ANTIGEN-SPECIFIC REGULATORY T-CELLS (TREG) WITH EFFECTOR T-CELL (TEFF) ANTIGEN RECEPTORS
JP7207661B2 (ja) * 2017-10-10 2023-01-18 国立大学法人広島大学 Ｐｌａｔｉｎｕｍ ＴＡＬＥＮを用いたＴ細胞受容体の完全置換技術
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN107827989A (zh) * 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
JP7101419B2 (ja) * 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
SG11202004026QA (en) 2017-10-30 2020-05-28 Pact Pharma Inc Primary cell gene editing
CN107916269B (zh) * 2017-11-17 2020-12-11 山东兴瑞生物科技有限公司 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
WO2019106163A1 (en) * 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
EP3724326A1 (en) * 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
CA3082204A1 (en) * 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3684399A1 (en) * 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN108559760A (zh) * 2018-01-09 2018-09-21 陕西师范大学 基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
EP3737765B2 (en) 2018-01-12 2025-01-22 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
WO2019143961A2 (en) * 2018-01-19 2019-07-25 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
WO2019157454A1 (en) * 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
EP3759131A4 (en) 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS
MX2020009272A (es) 2018-03-06 2021-01-08 Univ Pennsylvania Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
US11447769B2 (en) 2018-03-27 2022-09-20 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
US11649455B2 (en) 2018-03-30 2023-05-16 University Of Geneva Micro RNA expression constructs and uses thereof
IL277722B2 (en) 2018-04-02 2025-12-01 Pact Pharma Inc Peptide-mhc compacts
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
EP3773908A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
MA52207A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
CN108490174B (zh) * 2018-04-18 2022-06-24 上海尚珞生物医药科技有限公司 检测car-t细胞的方法及其应用
CN120442670A (zh) * 2018-04-26 2025-08-08 贝勒医学院 用于选择性靶向活化的致病性t细胞和nk细胞的自体/同种异体免疫防御受体
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
JP2021525518A (ja) * 2018-05-31 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 細胞をゲノム編集及び活性化するための方法
EP3802798A4 (en) * 2018-05-31 2022-05-11 Washington University CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR TREATMENT OF CANCER
CN110616188B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种通用型car-t细胞及其制备方法和应用
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020033366A1 (en) * 2018-08-08 2020-02-13 Nantbio, Inc. Recombinant cd1-restricted t cells and methods
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CN112805371B (zh) * 2018-09-21 2025-10-31 克莱格医学有限公司 基于CRISPR/Cas系统对细胞进行基因编辑的方法
JP7250031B2 (ja) * 2018-09-25 2023-03-31 公益財団法人微生物化学研究会 新規ウイルスベクターおよびその製造方法と使用方法
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113227374A (zh) * 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
BR112021008041A2 (pt) * 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com células imunitárias anti-cd33
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
CA3118830A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
WO2020103013A1 (en) * 2018-11-21 2020-05-28 Nanjing Bioheng Biotech Co., Ltd Modified t cells and uses thereof
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN109652378B (zh) * 2018-12-29 2020-04-24 广州百暨基因科技有限公司 一种功能增强的通用型car-t细胞及其制备方法和用途
CN109722437B (zh) * 2018-12-29 2020-01-07 广州百暨基因科技有限公司 一种通用型car-t细胞及其制备方法和用途
EP3911735A4 (en) * 2019-01-16 2023-07-12 Beam Therapeutics, Inc. MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
CN113557036A (zh) 2019-01-18 2021-10-26 奥泽生物疗法公司 基因编辑以改善关节功能
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
IL285534B2 (en) 2019-02-12 2025-04-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CA3130825A1 (en) 2019-02-22 2020-08-27 Garvan Institute Of Medical Research Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject
CN109913501B (zh) * 2019-03-01 2022-08-16 华东师范大学 一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
CN113906140B (zh) * 2019-03-18 2025-01-28 路德维格癌症研究院 A2/ny-eso-1特异性t细胞受体及其用途
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191378A1 (en) 2019-03-21 2020-09-24 Allogene Therapeutics, Inc. METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
MX2021013359A (es) * 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN112430575B (zh) * 2019-08-26 2024-01-19 深圳市菲鹏生物治疗股份有限公司 通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
KR20220051401A (ko) * 2019-09-06 2022-04-26 크리스퍼 테라퓨틱스 아게 배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
EP4034138A4 (en) * 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN114929862A (zh) * 2019-11-13 2022-08-19 克里斯珀医疗股份公司 用于制备表达嵌合抗原受体的t细胞的生产方法
KR20220097985A (ko) * 2019-11-13 2022-07-08 크리스퍼 테라퓨틱스 아게 Car-t 세포의 제조 방법
AU2020388690A1 (en) * 2019-11-20 2022-06-09 Cartherics Pty. Ltd. Method for providing immune cells with enhanced function
US20210155924A1 (en) * 2019-11-27 2021-05-27 Stitch Bio, Llc Methods and compositions for inducing tumor cell death
AU2020418199B2 (en) * 2020-01-02 2024-06-13 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Modified immune effector cell and preparation method therefor
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021147891A1 (zh) * 2020-01-21 2021-07-29 苏州克睿基因生物科技有限公司 一种经修饰的免疫效应细胞及其用途
US20210254005A1 (en) * 2020-01-23 2021-08-19 Kangstem Biotech Co., Ltd. Off-the-shelf stem cell and immune cell, and a pharmaceutical composition including the same
CA3174332A1 (en) 2020-04-21 2021-10-28 Jason PERERA Tcr/bcr profiling
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
WO2022012531A1 (zh) * 2020-07-14 2022-01-20 苏州克睿基因生物科技有限公司 一种经修饰的免疫细胞的制备方法
US20230248768A1 (en) * 2020-07-15 2023-08-10 Nanjing Bioheng Biotech Co., Ltd Engineered immune cell for allotransplantation
EP4182461A4 (en) * 2020-07-16 2025-03-19 Orthobio Therapeutics, Inc. GENE EDITING TO IMPROVE JOINT FUNCTION
IL300500A (en) * 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
JP2023546067A (ja) * 2020-10-13 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ｍＲＮＡ治療剤のためのＴ細胞のインビボ標的化
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
WO2022106731A1 (en) * 2020-11-23 2022-05-27 Ludwig-Maximilians-Universität München Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN112899227B (zh) * 2021-01-14 2022-09-13 中国科学院微生物研究所 一种调控辅助性t细胞功能的方法
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
US12577290B2 (en) 2021-03-04 2026-03-17 Allogene Therapeutics, Inc. FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
JP2024512368A (ja) * 2021-03-08 2024-03-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔ細胞機能障害を評価および治療するための組成物および方法
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
US20240390493A1 (en) * 2021-09-29 2024-11-28 The Johns Hopkins University Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN113980907B (zh) * 2021-12-24 2022-03-15 山东兴瑞生物科技有限公司 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
CN114591963B (zh) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA及利用其构建GM-CSF(-)细胞的方法
EP4583876A1 (en) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
US20260085331A1 (en) * 2022-09-19 2026-03-26 Emendobio Inc. Biallelic Knockout of PDCD1
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
EP4630567A2 (en) * 2022-12-09 2025-10-15 Research Institute at Nationwide Children's Hospital Chimeric antigen receptor (car) t cells and uses thereof
WO2024121426A1 (en) * 2022-12-09 2024-06-13 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Method for optimizing t cells for immuno-therapy
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
KR20250166108A (ko) * 2023-02-10 2025-11-27 난징 바이오흐엥 바이오테크 씨오., 엘티디 기능이 향상된 세포 치료법
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA120409A (en) 1909-05-13 1909-09-07 Hiram Lucas Piper Signal lamp
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6143291A (en) 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
ATE511400T1 (de) 2000-03-03 2011-06-15 Genetronics Inc Nukleinsäure-fomulierungen zur genverabreichung
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
AU2006342101A1 (en) 2005-12-07 2007-10-25 Genetronics, Inc Variable volume electroporation chamber and methods therefore
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
WO2007150054A2 (en) * 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2190468A2 (en) * 2007-08-30 2010-06-02 Genentech, Inc. Methods and compositions for modulating t cells
DK2356221T3 (en) 2008-10-24 2019-02-18 Wisconsin Alumni Res Found Pluripotent stem cells obtained by non-viral reprogramming
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
TWI465569B (zh) 2010-08-04 2014-12-21 Stembios Technologies Inc 體幹細胞
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3205636A1 (en) * 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
MX2014001222A (es) * 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
CA3285826A1 (en) * 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
FI2838548T3 (fi) * 2012-04-17 2023-10-02 Univ Washington Through Its Center For Commercialization HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
EP2852613B1 (en) 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
MX367730B (es) * 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
AU2013329186B2 (en) * 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
US20150037304A1 (en) 2013-03-12 2015-02-05 Sangamo Biosciences, Inc. Methods and compositions for modification of hla
EP3404111A1 (en) 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP6681837B2 (ja) 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
JP2017513472A (ja) 2014-04-11 2017-06-01 セレクティスＣｅｌｌｅｃｔｉｓ アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
WO2016054086A1 (en) 2014-09-30 2016-04-07 The Regents Of The University Of California Codon-optimized lentiviral vector for stem cell reprogramming
ES3015369T3 (en) * 2014-10-09 2025-05-05 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865582A4 (en) * 2018-09-30 2022-07-13 Beijing DCTY Biotech Co., Ltd. HAFFT1 CELL

Also Published As

Publication number Publication date
AU2015339744B2 (en) 2021-03-25
US12344843B2 (en) 2025-07-01
EP3215168A4 (en) 2018-08-15
JP2025089344A (ja) 2025-06-12
KR20170075013A (ko) 2017-06-30
PL3215166T3 (pl) 2024-08-26
JP7657474B2 (ja) 2025-04-07
CN107206024A (zh) 2017-09-26
US11203758B2 (en) 2021-12-21
KR20240075936A (ko) 2024-05-29
AU2021200118B2 (en) 2023-09-21
EA201790953A1 (ru) 2017-10-31
JP2023037006A (ja) 2023-03-14
KR20230098910A (ko) 2023-07-04
AU2021203981A1 (en) 2021-07-15
US20200407728A1 (en) 2020-12-31
US12570982B2 (en) 2026-03-10
JP2021058196A (ja) 2021-04-15
EP4219725A2 (en) 2023-08-02
AU2015339744A1 (en) 2017-04-27
KR20170074245A (ko) 2017-06-29
US12577567B2 (en) 2026-03-17
EP3215168B1 (en) 2023-08-02
AU2015339743C1 (en) 2021-04-22
KR20250005477A (ko) 2025-01-09
EP4427809A2 (en) 2024-09-11
US20170335331A1 (en) 2017-11-23
US20180312848A1 (en) 2018-11-01
US20220145306A1 (en) 2022-05-12
CN107206024B (zh) 2021-12-03
US20220154190A1 (en) 2022-05-19
CA2964953A1 (en) 2016-05-06
US20260043032A1 (en) 2026-02-12
AU2015339743A1 (en) 2017-04-27
AU2021200118A1 (en) 2021-03-25
WO2016069283A1 (en) 2016-05-06
US20170290858A1 (en) 2017-10-12
EP3215166A1 (en) 2017-09-13
EP3215168A1 (en) 2017-09-13
EP3215166A4 (en) 2018-12-05
CN114836385B (zh) 2025-04-04
JP2017535261A (ja) 2017-11-30
MX2023004169A (es) 2023-05-03
HK1243332A1 (en) 2018-07-13
US11208661B2 (en) 2021-12-28
CN107249606A (zh) 2017-10-13
BR112017008693A2 (pt) 2018-02-27
ES2983094T3 (es) 2024-10-21
AU2015339743B2 (en) 2020-11-05
WO2016069282A1 (en) 2016-05-06
EP3215166B1 (en) 2024-04-24
EP4219725A3 (en) 2023-08-30
JP2018500006A (ja) 2018-01-11
CN114836385A (zh) 2022-08-02
US20240279665A1 (en) 2024-08-22
KR102546296B1 (ko) 2023-06-21
JP7792114B2 (ja) 2025-12-25
AU2024203330A1 (en) 2024-08-08
EP4427809A3 (en) 2024-12-04
JP6879910B2 (ja) 2021-06-02
EP3215166B9 (en) 2024-11-27
MX2017005698A (es) 2017-06-29
KR102781429B1 (ko) 2025-03-18

Similar Documents

Publication Publication Date Title
US12570982B2 (en) Altering gene expression in modified T cells and uses thereof
HK40112241A (en) Altering gene expression in car-t cells and uses thereof
HK1243332B (en) Altering gene expression in modified t cells and uses thereof
EA051132B1 (ru) Изменение экспрессии гена в cart-клетках и их применения
EA040572B1 (ru) Изменение экспрессии гена в cart-клетках и их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241007

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250501

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250822

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250822

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250828

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250828

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250828

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250828

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250828

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006